Medivir announces new studies in phase III program for TMC435
Study in previous non-responder Hepatitis C genotype-1 infected patients
15-Mar-2012 -
Medivir AB announced that its oral, once daily investigational protease inhibitor TMC435, developed by Janssen Pharmaceuticals for the treatment of Hepatitis C virus (HCV), has commenced patient dosing and started screening in two new phase III clinical trials, HPC3001 and HPC3011, ...
hepatitis C
interferon
phase III studies